Search

Your search keyword '"McNamara, Mairéad G."' showing total 466 results
Start Over Author "McNamara, Mairéad G."
466 results on '"McNamara, Mairéad G."'

2. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Author

Oh, Do-Youn, He, Aiwu Ruth, Bouattour, Mohamed, Okusaka, Takuji, Qin, Shukui, Chen, Li-Tzong, Kitano, Masayuki, Lee, Choong-kun, Kim, Jin Won, Chen, Ming-Huang, Suksombooncharoen, Thatthan, Ikeda, Masafumi, Lee, Myung Ah, Chen, Jen-Shi, Potemski, Piotr, Burris, Howard A, III, Ostwal, Vikas, Tanasanvimon, Suebpong, Morizane, Chigusa, Zaucha, Renata E, McNamara, Mairéad G, Avallone, Antonio, Cundom, Juan E, Breder, Valeriy, Tan, Benjamin, Shimizu, Satoshi, Tougeron, David, Evesque, Ludovic, Petrova, Mila, Zhen, David B, Gillmore, Roopinder, Gupta, Vineet Govinda, Dayyani, Farshid, Park, Joon Oh, Buchschacher, Gary L, Jr, Rey, Felipe, Kim, Hyosung, Wang, Julie, Morgan, Claire, Rokutanda, Nana, Żotkiewicz, Magdalena, Vogel, Arndt, and Valle, Juan W

Published
2024
Full Text
View/download PDF

6. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

Author

McNamara, Mairéad G., Swain, Jayne, Craig, Zoe, Sharma, Rohini, Faluyi, Olusola, Wadsley, Jonathan, Morgan, Carys, Wall, Lucy R., Chau, Ian, Reed, Nick, Sarker, Debashis, Margetts, Jane, Krell, Daniel, Cave, Judith, Sothi, Sharmila, Anthoney, Alan, Bell, Christopher, Patel, Alkesh, Oughton, Jamie B., Cairns, David A., Mansoor, Wasat, Lamarca, Angela, Hubner, Richard A., and Valle, Juan W.

Published
2023
Full Text
View/download PDF

14. Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer.

Author

Alexander, Shaun, Aleem, Umair, Jacobs, Timothy, Frizziero, Melissa, Foy, Victoria, Hubner, Richard A., and McNamara, Mairéad G.

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, BILE duct tumors, TRASTUZUMAB, DRUG approval, ONCOGENES
Abstract

Simple Summary: Survival for patients with biliary tract cancer (BTC) is poor, especially in the advanced stage, where curative treatments are not available. While chemotherapy and immunotherapy are used in standard practice, antibody–drug conjugates (ADCs) have emerged as a novel therapy option. ADCs potentially enhance cancer cell death and reduce side effects. The anti-HER2 ADC Trastuzumab Deruxtecan (T-Dxd) has shown survival benefit for patients whose tumours are HER2-positive, including a subgroup of BTCs. In April 2024, the regulatory authority FDA approved T-Dxd for adults with unresectable or metastatic HER2-positive solid tumours, including BTCs, lacking other treatment options. Ongoing trials are exploring other potentially actionable BTC molecular alterations. This review will discuss the current evidence and ongoing research in this subject area. Background: Biliary tract cancers (BTCs) are aggressive in nature, often presenting asymptomatically until they are diagnosed at an advanced stage. Surgical resection or liver transplantation are potential curative options. However, a large proportion of patients present with incurable locally advanced or metastatic disease and most of these patients are only eligible for palliative chemotherapy or best supportive care. More recently, targeted therapies have proven beneficial in a molecularly selected subgroup of patients with cholangiocarcinoma who have progressed on previous lines of systemic treatment. However, only a minority of patients with BTCs whose tumours harbour specific molecular alterations can access these therapies. Methods: In relation to ADCs, studies regarding use of antibody–drug conjugates in cancer, particularly in BTCs, were searched in Embase (1974 to 2024) and Ovid MEDLINE(R) (1946 to 2024) to obtain relevant articles. Examples of current clinical trials utilising ADC treatment in BTCs were extracted from the ClinicalTrials.gov trial registry. Conclusions: Overall, this review has highlighted that ADCs have shown encouraging outcomes in cancer therapy, and this should lead to further research including in BTCs, where treatment options are often limited. The promising results observed with ADCs in various cancers underscore their potential as a transformative approach in oncology, warranting continued exploration and development and the need for education on the management of their specific toxicities. By addressing current challenges and optimising ADC design and application, future studies could potentially improve treatment outcomes for patients with BTCs and beyond, potentially in both early and advanced stage settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions.

Author

Netto, Daniel, Frizziero, Melissa, Foy, Victoria, McNamara, Mairéad G., Backen, Alison, and Hubner, Richard A.

Subjects
PANCREATIC duct, CANCER chemotherapy, SMALL molecules, RAS oncogenes, TUMOR microenvironment
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer-associated mortality, with a rising global incidence. A paucity of strong predictive risk factors mean screening programmes are difficult to implement. Historically, a lack of identifiable and actionable driver mutations, coupled with a relatively immunosuppressed tumour microenvironment, has led to a reliance on cytotoxic chemotherapy. The NAPOLI-3 trial has reported data supporting consideration of NALIRIFOX as a new first-line standard of care. Kirsten Rat Sarcoma Virus (KRAS) G12D mutations are present in >90% of all PDAC's; exciting breakthroughs in small molecule inhibitors targeting KRAS G12D may open new modalities of treatment, and therapies targeting multiple KRAS mutations are also in early clinical trials. Although immunotherapy strategies to date have been disappointing, combination with chemotherapy and/or small molecule inhibitors hold promise and warrant further exploration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Somatostatin Receptor Imaging with [18F]FET-bAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.

Author

Dubash, Suraiya, Barwick, Tara D., Kozlowski, Kasia, Rockall, Andrea G., Khan, Sairah, Khan, Sameer, Yusuf, Siraj, Lamarca, Angela, Valle, Juan W., Hubner, Richard A., McNamara, Mairéad G., Frilling, Andrea, Tan, Tricia, Wernig, Florian, Todd, Jeannie, Meeran, Karim, Pratap, Bhavesh, Azeem, Saleem, Huiban, Michael, and Keat, Nicholas

Published
2024
Full Text
View/download PDF

27. Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study

Author

Dubash, Suraiya, primary, Barwick, Tara D., additional, Kozlowski, Kasia, additional, Rockall, Andrea G., additional, Khan, Sairah, additional, Khan, Sameer, additional, Yusuf, Siraj, additional, Lamarca, Angela, additional, Valle, Juan W., additional, Hubner, Richard A., additional, McNamara, Mairéad G., additional, Frilling, Andrea, additional, Tan, Tricia, additional, Wernig, Florian, additional, Todd, Jeannie, additional, Meeran, Karim, additional, Pratap, Bhavesh, additional, Azeem, Saleem, additional, Huiban, Michael, additional, Keat, Nicholas, additional, Lozano-Kuehne, Jingky P., additional, Aboagye, Eric O., additional, and Sharma, Rohini, additional

Published
2024
Full Text
View/download PDF

30. Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre

Author

Clelland, Sarah, primary, Nuttall, Christina L., additional, Stott, Helen E., additional, Cope, Joseph, additional, Barratt, Natalie L., additional, Farrell, Kelly, additional, Eyong, Manyi V., additional, Gleeson, Jack P., additional, Lamarca, Angela, additional, Hubner, Richard A., additional, Valle, Juan W., additional, and McNamara, Mairéad G., additional

Published
2023
Full Text
View/download PDF

35. Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes

Author

Gray, Simon, primary, Letissier, Octave, additional, d’Abrigeon, Constance, additional, Shah, Dinakshi, additional, Wardell, Stephen, additional, Faluyi, Olusola, additional, Lamarca, Angela, additional, Hubner, Richard A., additional, Edeline, Julien, additional, Valle, Juan W., additional, and McNamara, Mairéad G., additional

Published
2023
Full Text
View/download PDF

38. Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes

Author

Gray, Simon, Letissier, Octave, D’abrigeon, Constance, Shah, Dinakshi, Wardell, Stephen, Faluyi, Olusola, Lamarca, Angela, Hubner, Richard A., Edeline, Julien, Valle, Juan W., and Mcnamara, Mairéad G.

Subjects
third-line, ampulla of Vater, biliary tract, cholangiocarcinoma, chemotherapy, targeted therapy, gallbladder, systemic therapy
Abstract

Phase 3 trials have established standard first-line (1L) and 2L systemic therapy options for patients with advanced biliary cancer (ABC). However, a standard 3L treatment remains undefined. Clinical practice and outcomes for 3L systemic therapy in patients with ABC were therefore evaluated from three academic centres. Included patients were identified using institutional registries; demographics, staging, treatment history, and clinical outcomes were collected. Kaplan-Meier methods were used to assess progression-free survival (PFS) and overall survival (OS). Ninety-seven patients, treated between 2006 and 2022, were included; 61.9% had intrahepatic cholangiocarcinoma. At the time of analysis, there had been 91 deaths. Median PFS from initiating 3L palliative systemic therapy (mPFS3) was 3.1 months (95%CI 2.0-4.1), while mOS3 was 6.4 months (95%CI 5.5-7.3); mOS1 was 26.9 months (95%CI 23.6-30.2). Among patients with a therapy-targeted molecular aberration (10.3%; n = 10; all received in 3L), mOS3 was significantly improved versus all other included patients (12.5 vs. 5.9 months; p = 0.02). No differences in OS1 were demonstrated between anatomical subtypes. Fourth-line systemic therapy was received by 19.6% of patients (n = 19). This international multicentre analysis documents systemic therapy use in this select patient group, and provides a benchmark of outcomes for future trial design.

Published
2023

40. Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

Author

Backen, Alison C., Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H, Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Pippa G., Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, McNamara, Mairéad G., Beare, Sandy, Bridgewater, John A., Dive, Caroline, and Valle, Juan W.

Published
2018
Full Text
View/download PDF

41. Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment—PanDA)

Author

Carnie, Lindsay E., primary, Shah, Dinakshi, additional, Vaughan, Kate, additional, Kapacee, Zainul Abedin, additional, McCallum, Lynne, additional, Abraham, Marc, additional, Backen, Alison, additional, McNamara, Mairéad G., additional, Hubner, Richard A., additional, Barriuso, Jorge, additional, Gillespie, Loraine, additional, Lamarca, Angela, additional, and Valle, Juan W., additional

Published
2023
Full Text
View/download PDF

47. Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy.

Author

d'Abrigeon, Constance, McNamara, Mairéad G., Le Sourd, Samuel, Lamarca, Angela, Lièvre, Astrid, Bourien, Héloïse, Peinoit, Alexandre, Uguen, Thomas, Hubner, Richard A., Valle, Juan W., and Edeline, Julien

Abstract

Background: Cirrhosis is a risk factor for intrahepatic cholangiocarcinoma (iCC). However, its exact prevalence is uncertain and its impact on the management of advanced disease is not established. Methods: Retrospective analysis of patients treated with systemic chemotherapy for advanced iCC in the 1st-line setting at 2 tertiary cancer referral centres. Cirrhosis was diagnosed based on at least one element prior to any treatment: pathological diagnosis, baseline platelets <150 × 109/L, portal hypertension and/or dysmorphic liver on imaging. Results: In the cohort of patients (n = 287), 82 (28.6%) had cirrhosis (45 based on pathological diagnosis). Patients with cirrhosis experienced more grade 3/4 haematologic toxicity (44% vs 22%, respectively, P = 0.001), and more grade 3/4 non-haematologic toxicity (34% vs 14%, respectively, P = 0.001) than those without. The overall survival (OS) was significantly shorter in patients with cirrhosis: median 9.1 vs 13.1 months for those without (HR = 1.56 [95% CI: 1.19–2.05]); P = 0.002), confirmed on multivariable analysis (HR = 1.48 [95% CI: 1.04–2.60]; P = 0.028). Conclusion: Cirrhosis was relatively common in patients with advanced iCC and was associated with increased chemotherapy-induced toxicity and shorter OS. Formal assessment and consideration of cirrhosis in therapeutic management is recommended. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results